Pierre-Yves Dietrich

Prof. Dr. Pierre-Yves Dietrich

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
NTNhu Nam Tran Thang
Nhu Nam Tran Thang
MDMadiha Derouazi
Madiha Derouazi
GPGéraldine Philippin
Géraldine Philippin
SASéverine Arcidiaco
Séverine Arcidiaco
WBWilma Di Berardino-Besson
Wilma Di Berardino-Besson
PWPaul Walker
Paul Walker
Immune infiltration of advanced human gliomas has been shown, but it is doubtful whether these immune cells affect tumor progression. It could be hypothesized that this infiltrate reflects recently recruited immune cells that are immediately overwhelmed by a high tumor burden. Alternatively, if there is earlier immune detection and infiltration of the tumor, the question arises as to when antitumor competency is lost. To address these issues, we analyzed a transgenic mouse model of spontaneous astrocytoma (GFAP-V12HA-ras mice), which allows the study of immune interactions with developing glioma, even at early asymptomatic stages. T cells, including a significant proportion of Tregs, are already present in the brain before symptoms develop, followed later by macrophages, natural killer cells, and dendritic cells. The effector potential of CD8 T-cells is defective, with the absence of granzyme B expression and low expression of IFN-γ, tumor necrosis factor, and interleukin 2. Overall, our results show an early defective endogenous immune response to gliomas, and local accumulation of immunosuppressive cells at the tumor site. Thus, the antiglioma response is not simply overwhelmed at advanced stages of tumor growth, but is counterbalanced by an inhibitory microenvironment from the outset. Nevertheless, we determined that effector molecule expression (granzyme B, IFN-γ) by brain-infiltrating CD8 T-cells could be enhanced, despite this unfavorable milieu, by strong immune stimuli. This potential to modulate the strong imbalance in local antiglioma immunity is encouraging for the development and optimization of future glioma immunotherapies. Cancer Res; 70(12); 4829–39. ©2010 AACR.

1 November 2022 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
HKHalah KUTAISH
Halah KUTAISH
LBLaura Bengtsson
Laura Bengtsson
PTPhilippe Matthias Tscholl
Philippe Matthias Tscholl
AMAntoine Marteyn
Antoine Marteyn
VBVincent Braunersreuther
Vincent Braunersreuther
VTVannary Tieng
Vannary Tieng
The repair of damaged articular cartilage is an unmet medical need. Chondrocyte-based cell therapy has been used to repair cartilage for over 20 years despite current limitations. Chondrocyte dedifferentiation upon expansion in monolayer is well known and is the main obstacle to their use as cell source for cartilage repair. Consequently, current approaches often lead to fibrocartilage, which is biomechanically different from hyaline cartilage and not effective as a long-lasting treatment. Here, we describe an innovative 3-step method to engineer hyaline-like cartilage microtissues, named Cartibeads, from high passage dedifferentiated chondrocytes. We show that WNT5A/5B/7B genes were highly expressed in dedifferentiated chondrocytes and that a decrease of the WNT signaling pathway was instrumental for full re-differentiation of chondrocytes, enabling production of hyaline matrix instead of fibrocartilage matrix. Cartibeads showed hyaline-like characteristics based on GAG quantity and type II collagen expression independently of donor age and cartilage quality. In vivo, Cartibeads were not tumorigenic when transplanted into SCID mice. This simple 3-step method allowed a standardized production of hyaline-like cartilage microtissues from a small cartilage sample, making Cartibeads a promising candidate for the treatment of cartilage lesions.

21 September 2022 in European Journal of Cancer Care
Verified
Journal Article
Open access
CAChantal Arditi
Chantal Arditi
MEManuela Eicher
Manuela Eicher
SCSara Colomer-Lahiguera
Sara Colomer-Lahiguera
CBChristine Bienvenu
Christine Bienvenu
Sandro AnchisiSandro Anchisi
Sandro Anchisi
IPIsabelle Peytremann‐Bridevaux
Isabelle Peytremann‐Bridevaux
The objectives were to describe patients' experiences of cancer care in Switzerland and explore the variation of these experiences by type of cancer. The Swiss Cancer Patient Experiences (SCAPE) study was a cross‐sectional, multicentre survey conducted in 2018. Adult patients (n = 7145) with breast, prostate, lung, colorectal, skin or haematological cancer from four large hospitals in French‐speaking Switzerland were invited to complete a survey. Logistic regressions were used to assess whether experiences varied according to cancer type, adjusting for confounders. Of the 3121 persons who returned the survey (44% response rate), 2755 reporting an eligible cancer were included in the analyses. Participants' average score for overall care was 8.5 out of a maximum score of 10. Higher rates of positive experiences were found for nurse consultations (94%), diagnostic tests (85%) and inpatient care (82%). Lower positive responses were reported for support for people with cancer (70%), treatment decisions (66%), diagnosis (65%) and home care (55%). We observed non‐systematic differences in experiences of care by cancer type. This large study identified that cancer patient experiences can be improved in relation to communication, information and supportive care aspects. Improvement efforts should target these areas of care to enhance responsiveness of cancer care.

12 June 2023 in International Journal of Cancer
Verified
Journal Article
Open access
LRLou Romanens
Lou Romanens
PCPrasad Chaskar
Prasad Chaskar
RMRachel Marcone
Rachel Marcone
SRStephan Ryser
Stephan Ryser
JTJean-Christophe Tille
Jean-Christophe Tille
SLSana Intidhar Labidi‐Galy
Sana Intidhar Labidi‐Galy
The spatial distribution of tumor‐infiltrating lymphocytes (TIL) predicts breast cancer outcome and response to systemic therapy, highlighting the importance of an intact tissue structure for characterizing tumors. Here, we present ST‐FFPE, a spatial transcriptomics method for the analysis of formalin‐fixed paraffin‐embedded samples, which opens the possibility of interrogating archival tissue. The method involves extraction, exome capture and sequencing of RNA from different tumor compartments microdissected by laser‐capture, and can be used to study the cellular composition of tumor microenvironment. Focusing on triple‐negative breast cancer (TNBC), we characterized T cells, B cells, dendritic cells, fibroblasts and endothelial cells in both stromal and intra‐epithelial compartments. We found a highly variable spatial distribution of immune cell subsets among tumors. This analysis revealed that the immune repertoires of intra‐epithelial T and B cells were consistently less diverse and more clonal than those of stromal T and B cells. T‐cell receptor (TCR) sequencing confirmed a reduced diversity and higher clonality of intra‐epithelial T cells relative to the corresponding stromal T cells. Analysis of the top 10 dominant clonotypes in the two compartments showed a majority of shared but also some unique clonotypes both in stromal and intra‐epithelial T cells. Hyperexpanded clonotypes were more abundant among intra‐epithelial than stromal T cells. These findings validate the ST‐FFPE method and suggest an accumulation of antigen‐specific T cells within tumor core. Because ST‐FFPE is applicable for analysis of previously collected tissue samples, it could be useful for rapid assessment of intratumoral cellular heterogeneity in multiple disease and treatment settings.

12 May 2020 in Health Science Reports
Verified
Journal Article
Open access
PDF file
AGAnne Gerber
Anne Gerber
ALAndré Da Silva Lopes
André Da Silva Lopes
NSNatacha Szüts
Natacha Szüts
Michael SimonMichael Simon
Michael Simon
VRViviane Ribordy‐Baudat
Viviane Ribordy‐Baudat
MEManuela Eicher
Manuela Eicher
Background and aims: The occurrence rate of adverse events (AEs) related to care among hospitalized oncology patients in Switzerland remains unknown. The primary objective of this study was to describe, for the first time, the occurrence rate, type, severity of harm, and preventability of AEs related to care, reported in health records of hospitalized hematological and solid‐tumor cancer patients in three Swiss hospitals.Methods: Using an adapted version of the validated Global Trigger Tool (GTT) from the Institute for Healthcare Improvement, we conducted a retrospective record review of patients discharged from oncology units over a 6‐week period during 2018. Our convenience sample included all records from adult patients (≥18 years of age), diagnosed with cancer, and hospitalized (>24 hours). Per the GTT method, two trained nurses independently assessed patient records to identify AEs using triggers, and physicians from the included units analyzed the consensus of the two nurses. Together, they assessed the severity and preventability of each AE.Results: From the sample of 224 reviewed records, we identified 661 triggers and 169 AEs in 94 of them (42%). Pain related to care was the most frequent AE (n = 29), followed by constipation (n = 17). AEs rates were 75.4 per 100 admissions and 106.6 per 1000 patient days. Most of the identified AEs (78%) caused temporary harm to the patient and required an intervention. Among AEs during hospitalization (n = 125), 76 (61%) were considered not preventable, 28 (22%) preventable, and 21 (17%) undetermined.Conclusion: About half of the hospitalized oncology patients suffered from at least one AE related to care during their hospitalization. Pain, constipation, and nosocomial infections were the most frequent AEs. It is, therefore, essential to identify AEs to guide future clinical practice initiatives to ensure patient safety.

1 January 2001
Verified
Book Chapter
Closed access
PWPaul Walker
Paul Walker
PDPierre-Yves Dietrich
Pierre-Yves Dietrich